BioBeam 940

BioBeam™ 940 – Infra light therapy for Pain Relief

Introducing the BioBeam™ 940 – a drug free, pain free, risk free, low level narrow band red light medical device to alleviate chronic pain associated with all types of arthritis such as osteoarthritis, rheumatic and rheumatoid arthritis, gout arthritis and pains in small joints, and for the treatment of soft tissue disorders, such as tendonitis. 

The BioBeam™ 940 can either be used as an alternative or in conjunction with pharmaceuticals

and physiotherapy.

The BioBeam™ 940 is an effective photo-therapy pain. The BioBeam™ 940 is a Class 2A phototherapeutic medical device and complies with Annex VI of the Medical Device Directive 93/42/EEC and is CE certified (CE 0473).

Double blind tests have documented that BioBeam treatment significantly lessens pain associated with chronic tendonitis and facet joint arthritis. Patients with degenerative knee diseases and chondromalacia patella showed a significant improvement in pain, power, ability to negotiate stairs, and walking tolerance.

Phototherapy is a medical field where patients are treated with light rays. Sometimes sunlight is used in phototherapy. The light source of the BioBeam™ 940 , which has special healing properties, is an example of a light source that is not found in nature. BioBeam™ 940  uses narrow band invisible infrared light to relieve symptomatic joint pain in rheumatic or arthritic conditions such as back pain and knee pain.

This light source possesses special qualities accelerating the natural healing process, resulting in

fewer medical treatments and medication. Please note that the illumination treatments with BioBeam™ 940 are intended to be carried out in conjunction with treatment prescribed by a licensed medical practitioner, and are not intended to replace such medical treatment, unless specifically recommended by a physician. In all cases, it is strongly recommended to consult with a physician before use. 

(Note: The BioBeam™ 940 will be sold throughout Europe, the Far East, and Latin America. In U.S. markets, the BioPro™ will be marketed for the treatment of chronic pain.)